1) Strategic Overview & Leadership Insights - Biogen has stabilized its business after four years of declining revenue and profit, emphasizing the need for investment in growth rather than just cost-cutting. - The company has shifted 90% of its commercial costs to focus on growth products, which generated $850 million in Q1 2026, up 12% YoY. - The acquisition of Apellis is expected to enhance Biogen's commercial growth portfolio, with anticipated EPS accretion in 2027.

2) Financial Performance & Segment Results - Total revenue for Q1 2026 was $2.5 billion, a 2% increase YoY, with GAAP diluted EPS at $2.15 (up 31% YoY) and non-GAAP diluted EPS at $3.57 (up 18% YoY). - LEQEMBI revenue reached $168 million, up 74% YoY, while SKYCLARYS generated $151 million, reflecting a 22% growth YoY. - Growth products now outpace traditional MS products in revenue generation, indicating a successful shift in focus.

3) Operational Developments & Product Plans - The high-dose SPINRAZA has been approved in the U.S. and Japan, with positive early adoption rates, indicating potential for franchise stabilization and growth. - Biogen's late-stage pipeline is progressing well, with multiple data readouts expected in 2026, including pivotal studies for Litifilimab and Salanersen. - The company is actively exploring early-stage development opportunities and maintaining a disciplined approach to costs while investing in growth.

4) Challenges & Market Dynamics - The company faces competitive pressures in the ophthalmology market with SYFOVRE, where it aims to differentiate based on long-term efficacy data. - There are ongoing concerns about macroeconomic factors and potential tariffs, but the company does not expect a material impact on its business in 2026. - The transition to high-dose SPINRAZA and the introduction of subcutaneous LEQEMBI are critical to maintaining treatment persistence and market share.

5) Guidance & Outlook - Biogen maintains its guidance for 2026, expecting continued growth driven by its pipeline and the Apellis acquisition. - The company anticipates a $0.20 EPS impact from acquired IPR&D charges in Q1 and an additional $0.80 in Q2 due to ongoing investments in its pipeline. - Future guidance will incorporate the Apellis transaction once closed, with expectations for significant contributions from SYFOVRE and Empaveli.

Bottom line: Biogen is on a positive trajectory with a strong start to 2026, driven by strategic investments in growth products and a promising pipeline. The upcoming Apellis acquisition is expected to further enhance its growth profile, making it an attractive prospect for shareholders.